News

As part of NeurologyLive®'s Year in Review, take a look at the top most-read news in movement disorders in 2022.

These were the most-read FDA approval stories that were part of our coverage in 2022, brought to you as part of NeurologyLive®'s Year in Review.

These were the most-watched interviews with experts in movement disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

Marketed as Briumvi, the TG Therapeutics treatment becomes the third anti-CD20 agent approved for relapsing multiple sclerosis and is expected to become available in the first quarter of 2023.

The executive director of Banner Alzheimer’s Institute discussed the efforts being done within the field to improve prevention and therapeutics for Alzheimer disease.

These were the most-watched interviews with experts in multiple sclerosis that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in stroke and cerebrovascular disease in 2022.

These were the most-watched episodes of 2022 from our various video series, brought to you as part of NeurologyLive®'s Year in Review.

These were the most-watched interviews with experts in headache and migraine that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

Here's some of what is coming soon to NeurologyLive® this week.

At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about sleep testing for patients with epilepsy. [WATCH TIME: 3 minutes]

These were the most-watched interviews with experts in epilepsy and seizure disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neurology news in 2022.

Neurology News Network for the week ending December 24, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 23, 2022.

As part of NeurologyLive®'s Year in Review, take a look at our top news articles in headache and migraine in 2022.

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the neurodevelopmental impacts delaying seizures could lead to in tuberous sclerosis complex. [WATCH TIME: 2 minutes]

The past year has provided great steps forward in sleep science, and coupled with the lingering difficulties in care and the COVID-19 pandemic’s effects, the field is coming to a head to make sleep health a public health priority.

These were the most-watched interviews with experts in dementia that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2022.

The associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital spoke about sleep disorders and epilepsy in adults at the 2022 AES annual meeting. [WATCH TIME: 5 minutes]

As part of NeurologyLive®'s Year in Review, take a look at the most-read news stories in epilepsy and seizure disorders in 2022.

Clinician perceived cognitive performance was significantly predicted by multiple factors, including cognitive scores, physical disability, age, and depression.

The neuropsychologist at Rutgers University, in New Brunswick, New Jersey, spoke about the different types of nonpharmacological digital interventions for multiple sclerosis. [WATCH TIME: 4 minutes]

A review of randomized controlled trials on balance interventions highlighted the effects for improved mobility and balance in multiple sclerosis.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read question-and-answer interviews we've conducted with experts in various neurology specialties in 2022.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news stories in Alzheimer disease and dementia in 2022.

The director of the Headache Center at Allegheny Health Network provided perspective on the process of identifying a patient with chronic migraine and initiating a proper treatment plan. [WATCH TIME: 7 minutes]